Effect of Survivin Down-Regulation by Egr1-Survivin shRNA Combined with Radiotherapy on Radiosensitivity of EsophagealSquamous Carcinoma

DOI :
Tweet about this on TwitterShare on FacebookEmail this to someoneShare on Google+

Yin Lv; Jinrong Zhang; Yanrong Lu; Xin Zhang & Haifeng Wang

Summary

This study is to investigate the effect of survivin down-regulation by Egr1-survivin shRNA combined with radiotherapy on the apoptosis and radiosensitivity of esophageal squamous cell carcinoma ECA109 and KYSE150 cells. ECA109 and KYSE150 cells were transfected with Egr1-survivin shRNA, and then treated with radiotherapy. After 24 h, the mRNA and protein levels of Egr1-survivin were detected by qPCR and Western-Blot. Cell cycle and apoptosis were detected by flow cytometry. Western blot also detected levels of cleavaged Caspase 3 and Caspase 9. YM155 was used as a positive control to inhibit survivin expression. The levels of survivin mRNA and protein in ECA109 and KYSE150 cells treated with Egr1-survivin shRNA combined with radiotherapy were significantly lower than those of the blank control group, the empty vector control group, and, the YM155 + radiotherapy group (P<0.05). Meanwhile, after survivin down-regulation, the ratio of G2 to S phase of ECA109 and KYSE150 cells increased significantly, leading to significant G2 and S phase arrest. Additionally, apoptosis of ECA109 and KYSE150 cells increased significantly (P <0.01). Further, protein levels of cleavaged Caspase 3 and Caspase 9 significantly increased in Egr1-survivin shRNA combined with radiotherapy group. Egr1-survivin shRNA combined with radiotherapy can down-regulate survivin expression, which further increases the apoptosis, and enhances the radiosensitivity of ECA109 and KYSE150 cells.

KEY WORDS: Esophageal squamous cell carcinoma; Survivin; Gene-radiotherapy; Radiosensitivity.

How to cite this article

LV, Y.; ZHANG, J.; LU, Y.; ZHANG, X. & WANG, H. Effect of survivin down-regulation by Egr1-survivin shRNA combined with radiotherapy on radiosensitivity of esophageal squamous carcinoma. Int. J. Morphol., 41(6):1712-1719, 2023.